论文部分内容阅读
多药耐药（ＭＤＲ）是影响肿瘤化疗成功的重要障碍。早期发现ＭＤＲ，从而选择较敏感的治疗药物，具有临床实用价值。最近发现，(９９m)Ｔｃ－甲氧基异丁基异腈（ｍｅｔｈｏｘｙ ｉｓｏｂｕｔｙｌｉｓｏｎｉｔｒｉｌｅ，简称 ＭＩＢＩ）和某些细胞毒药物同为 ｍｄｒ１基因表达的Ｐ－糖蛋白（Ｐ－ｇｐ）的作用废物，Ｐ－ｇｐ能将它们转运出细胞，使化疗无效，也使肿瘤不表现放射性浓集。从而提示可以用简便、无创的核医学显像方法，于化疗之前预测体内肿瘤细胞的ＭＤＲ状况，协助选择治疗药物；并可在治疗过程中随时监测ＭＤＲ的变化，以及评价药物逆转ＭＤＲ的效果。
Multidrug resistance (MDR) is an important obstacle to the success of cancer chemotherapy. Early detection of MDR, thus the choice of more sensitive therapeutic drugs, has clinical practical value. Recently, it has been found that (99m) methoxyisobutylisonitrile (MIBI) and some cytotoxic drugs are the wastes of P-glycoprotein (P-gp) expressed by mdr1 gene. P-gp Transporting them out of the cell renders the chemotherapy ineffective and renders the tumor not radioactively concentrated. This suggests that MDR status of tumor cells in vivo can be predicted by a simple and non-invasive nuclear medicine imaging method before chemotherapy to help select the treatment drugs. The changes of MDR can be monitored at any time during treatment, and the effect of drug reversal on MDR can be evaluated.